Single-dose pharmacokinetics and pharmacodynamics of RWJ 67657, a specific p38 mitogen-activated protein kinase inhibitor: a first-in-human study.

@article{Parasrampuria2003SingledosePA,
  title={Single-dose pharmacokinetics and pharmacodynamics of RWJ 67657, a specific p38 mitogen-activated protein kinase inhibitor: a first-in-human study.},
  author={Dolly A. Parasrampuria and Peter de Boer and Daksha Desai-Krieger and Andrew T. Chow and C. Richard Jones},
  journal={Journal of clinical pharmacology},
  year={2003},
  volume={43 4},
  pages={406-13}
}
The objective of this study was to investigate the pharmacokinetics and ex vivo pharmacodynamics of increasing doses of RWJ 67657, along with the effect of food at one dose level in a first-in-human (FIH) study. This was a placebo-controlled, double-blind, randomized trial in healthy male subjects. Subjects received increasing doses of RWJ 67657 or placebo as a single oral dose (0.25-30 mg/kg) under fasting conditions. The effect of food was investigated for the 10-mg/kg dose. Plasma… CONTINUE READING